Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

the Company's filings with the Securities and Exchange Commission.

    APPENDIX
    1. Principal Risks and Uncertainties
    RISKS RELATED TO THE GROUP'S BUSINESS
    The Group's new products may not be a commercial success

Shire has launched a number of new products in the last four years, including key new products ELAPRASE, VYVANSE, LIALDA, FIRAZYR and FOSRENOL (Rest of World ('ROW')). The commercial success of these new products, as well as other new products that the Group may launch in the future, will depend on their approval and acceptance by physicians, patients and other key decision-makers, as well as the timing of the receipt of marketing approvals, the scope of marketing approvals as reflected in the product's label, the countries in which such approvals are obtained, the authorization of price and reimbursement in those countries where price and reimbursement is negotiated, and safety, efficacy, convenience and cost-effectiveness of the product as compared to competitive products.

The Group may not be able to grow revenues in its new products as quickly as anticipated if any or all of the following occur:

    - if competitive products are genericised and the impact on the market
      negatively affects the prescribing of branded treatments for the
      indications that the Group's new products treat;

    - if there are unanticipated adverse events experienced with the Group's
      new products not seen in clinical trials that impact the physician's
      willingness to prescribe the Group's new products;

    - if issues arise from clinical trials being conducted for post marketing
      purposes or for registration in another country or regulatory agencies
      in one country act in a way that causes concern for prescribers or
      patients in another country;

    - if patients, payors or physicians favor older treatments over newer
      treatments;

    -
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... NY (PRWEB) September 11, 2014 Entries are ... Awards—the only awards where peers and colleagues within the healthcare ... Pharma Choice Awards recognize the very best in healthcare creative ... judged by peers in the health and wellness industry. All ... vote for the top campaigns in each category. , ...
(Date:9/11/2014)... 11, 2014 Genera Energy Inc ... and supply chain advancements, recently introduced its newest feedstock ... delivers a consistent biomass product to a customer’s specifications ... lower cost. , “After producing and harvesting a ... to convert a field crop into a uniform format ...
(Date:9/11/2014)... (PRWEB) September 11, 2014 Central Florida ... announce his partnerships with several Brevard County animal hospitals ... Christiansen has been working in the area since January ... animals since 2008, and is happy to now offer ... years Dr. Christiansen has used stem cell therapy with ...
(Date:9/10/2014)... , Schweiz, September 11, 2014 ... Eierstockkrebs, die bei der Jahresversammlung der Europäischen ... bekräftigen die komplette Tumorprofilierung als "Wendepunkt" für ... Caris Registry™ zeigte ein deutlich längeres Überleben ... Eileiter- oder primär peritonealem Krebs, denen Behandlungen ...
Breaking Biology Technology:PM360 Now Accepting Entries for 2014 Pharma Choice Awards 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 3Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 2Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 3Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 4Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 5
... in a series of articles on developing start-up companies ... article focused on the tax law implications of employees ... unemployment insurance. , , Madison, Wis. ... test for determining independent contractor status. Although this test ...
... that a CIO's head has to be on a swivel. ... consistent theme during the Fusion 2007 CEO-CIO Symposium , ... directions, and risk management has surpassed security as the paramount ... opening keynote, where John Swainson, chief executive of CA ...
... web-centric business sector continued its crash in 2001, the directors ... their Wisconsin-based business unit. Their decision was only delayed when ... meeting in New York scheduled for that tragic day. , ... Dan Maynard pleaded with board members to keep the division ...
Cached Biology Technology:Early Stage, Step 8: Misclassifying workers brings risk 2Early Stage, Step 8: Misclassifying workers brings risk 3Early Stage, Step 8: Misclassifying workers brings risk 4Early Stage, Step 8: Misclassifying workers brings risk 5Fusion 2007: IT threats make risk management paramount 2Fusion 2007: IT threats make risk management paramount 3Connecture's Maynard finds IT business opportunity in adversity 2Connecture's Maynard finds IT business opportunity in adversity 3Connecture's Maynard finds IT business opportunity in adversity 4Connecture's Maynard finds IT business opportunity in adversity 5Connecture's Maynard finds IT business opportunity in adversity 6
(Date:9/11/2014)... are more than 300,000 cases of Lyme disease in the ... to the CDC were concentrated heavily in the Northeast and ... In fact, the disease gets its name from the northeastern ... However, a new article published in the Journal of ... disease Ixodes scapularis , also known as blacklegged ...
(Date:9/11/2014)... known for her work as a high-energy experimental particle ... international consortium of scientists who detected the Higgs boson ... Hadron Collider. , But Bean, a professor of physics ... a long-running passion for engaging the public with science. ... artists and museum educators in the creation of "Quarked," ...
(Date:9/11/2014)... A new study led by the Wildlife Conservation ... where leopards prowl at night, it,s not livestock that,s ... friend. , The study, which looked at scat samples ... that 87 percent of their diet was made up ... most common prey item at 39 percent and domestic ...
Breaking Biology News(10 mins):Physics researcher to advise faith-based office in US Department of State 2Study: Cat bites dog 2
... men die of prostate cancer. It,s Australia,s second worst ... cancer on women. Current therapies for prostate ... the tumour or cutting off the supply of the ... impotence. Growing cells need an essential nutrient, the ...
... of the scientific and technical publishing business of John Wiley ... Society Located in Taipei have signed an agreement to closely ... Chemical Society . The journal will be available online from ... most extensive multidisciplinary collections of online resources, used by 10 ...
... distinct from hematopoietic cells, are an essential component ... for the long-term maintenance of hematopoietic stem cells ... stromal cells regulate the proliferation and differentiation of ... factors and extracellular matrix, and through physical cell-cell ...
Cached Biology News:Starving prostate cancer 2Journal of the Chinese Chemical Society expands international reach with Wiley-VCH 23-D long-term bone marrow culture to analyze stromal cell biological function 2
...
...
... derived from the Spodoptera frugiperda Sf21 cell line ... transfections, plaque assays, virus production, and protein expression. ... optimizes recovery of viable cells after thawing. They ... Cell Medium and can also be grown in ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: